This document discusses the Renin-Angiotensin-Aldosterone System and various clinical trials related to treating chronic kidney disease in patients with type 2 diabetes, including the CREDENCE trial of canagliflozin and phase 2 trials of finerenone. It also mentions inflammation and fibrosis as well as providing abbreviations.
This document discusses the Renin-Angiotensin-Aldosterone System and various clinical trials related to treating chronic kidney disease in patients with type 2 diabetes, including the CREDENCE trial of canagliflozin and phase 2 trials of finerenone. It also mentions inflammation and fibrosis as well as providing abbreviations.
This document discusses the Renin-Angiotensin-Aldosterone System and various clinical trials related to treating chronic kidney disease in patients with type 2 diabetes, including the CREDENCE trial of canagliflozin and phase 2 trials of finerenone. It also mentions inflammation and fibrosis as well as providing abbreviations.
Guidelines Treatment of CKD in T2D CREDENCE Dedicated Renal Outcomes Trial With Canagliflozin The Role of Inflammation and Fibrosis Phase 2 Clinical Trials With Finerenone Abbreviations